AbbVie Inc. $ABBV Shares Purchased by Roberts Glore & Co. Inc. IL

Roberts Glore & Co. Inc. IL raised its position in AbbVie Inc. (NYSE:ABBV) by 5.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,477 shares of the company’s stock after purchasing an additional 1,571 shares during the quarter. AbbVie accounts for approximately 1.7% of Roberts Glore & Co. Inc. IL’s portfolio, making the stock its 12th largest position. Roberts Glore & Co. Inc. IL’s holdings in AbbVie were worth $5,657,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. TD Capital Management LLC lifted its stake in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie during the second quarter worth about $25,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the second quarter worth about $28,000. Cypress Capital Management LLC WY acquired a new stake in shares of AbbVie during the first quarter worth about $35,000. Finally, Bear Mountain Capital Inc. boosted its stake in shares of AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several recent research reports. Evercore ISI upped their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. HSBC set a $225.00 price objective on AbbVie in a research note on Thursday, October 2nd. Morgan Stanley lifted their target price on AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Finally, BMO Capital Markets upped their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Price Performance

Shares of NYSE ABBV opened at $218.92 on Friday. The stock’s 50-day simple moving average is $223.24 and its 200-day simple moving average is $202.50. The firm has a market capitalization of $386.92 billion, a PE ratio of 104.25, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is presently 524.24%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares of the company’s stock, valued at approximately $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.25% of the stock is owned by corporate insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.